Literature DB >> 22927094

Pathogenesis of Parkinson's disease.

Etienne C Hirsch1, Peter Jenner, Serge Przedborski.   

Abstract

Parkinson's disease is a common adult-onset neurodegenerative disorder whose pathogenesis remains essentially unknown. Currently, it is believed that the neurodegenerative process in Parkinson's disease is a combination of both cell-autonomous and non-cell-autonomous mechanisms. Proposed cell-autonomous mechanisms include alterations in mitochondrial bioenergetics, dysregulation of calcium homeostasis, and impaired turnover of mitochondria. As for the proposed non-cell-autonomous mechanisms, they involve prion-like behavior of misfolded proteins and neuroinflammation. This suggests that cell death in Parkinson's disease is caused by a multifactorial cascade of pathogenic events and argues that effective neuroprotective therapy for Parkinson's disease may have to rely on multiple drug interventions.
Copyright © 2013 Movement Disorders Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22927094     DOI: 10.1002/mds.25032

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  90 in total

1.  Polyphenols from Toona sinensiss Seeds Alleviate Neuroinflammation Induced by 6-Hydroxydopamine Through Suppressing p38 MAPK Signaling Pathway in a Rat Model of Parkinson's Disease.

Authors:  Wenxin Zhuang; Meiyun Cai; Wanzhong Li; Chao Chen; Yanqiang Wang; E Lv; Wenyu Fu
Journal:  Neurochem Res       Date:  2020-06-17       Impact factor: 3.996

Review 2.  Therapy for Parkinson's disease: what is in the pipeline?

Authors:  Fabrizio Stocchi
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

3.  The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions.

Authors:  Tanuja Bordia; Matthew McGregor; Roger L Papke; Michael W Decker; J Michael McIntosh; Maryka Quik
Journal:  Exp Neurol       Date:  2014-09-28       Impact factor: 5.330

Review 4.  Modeling and imaging cardiac sympathetic neurodegeneration in Parkinson's disease.

Authors:  Valerie Joers; Marina E Emborg
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-03-20

Review 5.  Nurr1-Based Therapies for Parkinson's Disease.

Authors:  Jie Dong; Song Li; Jing-Lin Mo; Huai-Bin Cai; Wei-Dong Le
Journal:  CNS Neurosci Ther       Date:  2016-03-25       Impact factor: 5.243

6.  Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.

Authors:  Richard Gordon; Neeraj Singh; Vivek Lawana; Anamitra Ghosh; Dilshan S Harischandra; Huajun Jin; Colleen Hogan; Souvarish Sarkar; Dharmin Rokad; Nikhil Panicker; Vellareddy Anantharam; Anumantha G Kanthasamy; Arthi Kanthasamy
Journal:  Neurobiol Dis       Date:  2016-05-02       Impact factor: 5.996

Review 7.  Chemiexcitation and Its Implications for Disease.

Authors:  Douglas E Brash; Leticia C P Goncalves; Etelvino J H Bechara
Journal:  Trends Mol Med       Date:  2018-05-08       Impact factor: 11.951

Review 8.  Parkinson's disease: an update on pathogenesis and treatment.

Authors:  Tom Foltynie; Joshua Kahan
Journal:  J Neurol       Date:  2013-04-16       Impact factor: 4.849

9.  Neuroprotective Effects of Paeoniflorin on 6-OHDA-Lesioned Rat Model of Parkinson's Disease.

Authors:  Xiao-Su Gu; Fen Wang; Cai-Yi Zhang; Cheng-Jie Mao; Jing Yang; Ya-Ping Yang; Sha Liu; Li-Fang Hu; Chun-Feng Liu
Journal:  Neurochem Res       Date:  2016-07-22       Impact factor: 3.996

10.  D-polyglutamine amyloid recruits L-polyglutamine monomers and kills cells.

Authors:  Karunakar Kar; Irene Arduini; Kenneth W Drombosky; Patrick C A van der Wel; Ronald Wetzel
Journal:  J Mol Biol       Date:  2013-11-28       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.